NYMOX Update
07 juil. 2023 17h02 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing information to address requests it has received for further...
Nymox Delisting from NASDAQ
05 juil. 2023 18h11 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained...
Nymox Provides Current Update
10 mai 2023 10h00 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide a mid-2nd quarter update on ongoing activities. The Company...
Nymox Provides Corporate Update
03 avr. 2023 09h30 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide a current update on the Company's ongoing projects. The...
Nymox Announces Appointment of Christopher R. Riley as Chief Financial Officer
21 mars 2023 10h00 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce the appointment of Christopher R. Riley as Chief Financial...
Nymox Officially Granted Extension to Regain Listing Requirements
15 mars 2023 09h30 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) has officially been granted by NASDAQ an additional period until July 3, 2023 to...
Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review
15 févr. 2023 11h50 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that the Company's recent submission of Fexapotide Triflutate...
NYMOX Appeals Deficiency Letter
06 janv. 2023 16h30 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) reports that on January 4, 2023 the Company received a deficiency letter from The...
NYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPH
05 déc. 2022 09h30 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that a new formal submission has been made by the...
May 2023 Market Cap Requirement Update
25 nov. 2022 15h10 HE
|
Nymox Pharmaceutical Corporation
IRVINE, Calif., Nov. 25, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) reports that on November 18, 2022 the Company received a deficiency letter from...